TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06158126

Intervention type: DRUG
Intervention: Initiating daily oral PrEP during pregnancy
Description: Group 1a, will include pregnant women who initiate oral PrEP at enrollment into the study.

Intervention type: DRUG
Intervention: Already using daily oral PrEP at the time of pregnancy diagnosis
Description: Group 1b will include women already using daily oral PrEP at the time of pregnancy diagnosis and enrollment in the study.
Study: NCT05677854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health literacy based motivaonal interview
Description: Motivational interviewing technique was used based on health literacy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health literacy based health education
Description: Health education based on health literacy was used.
Study: NCT05307081

Intervention type: DRUG
Intervention: Artificial Tears
Description: Artificial Tears are an FDA approved intervention
Study: NCT03598946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urinary test
Description: Women use a home urinary test themselves
Study: NCT05680090

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligent system for eye emergency triage and primary diagnosis
Description: An intelligent triage and diagnostic system for ophthalmic emergencies has been developed. In the prospective test, patients with acute ocular symptoms can achieve remote self-triage and primary diagnosis after uploading metadata and ocular images.
Study: NCT05042570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: * This technique will be performed using instruments of different sizes, shapes and treatment styles.~* During the application, instruments will be applied to loosen the muscle tissue and fascia by gliding on the tissue at certain angles.~* The muscle groups to be treated with IASTM are gastrocnemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* The instrument will be sterilized before treatment.~* IASTM treatment will be applied without damaging the tissue after massaging cream is applied to the muscle fibers with the instrument.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercises
Description: * The muscle groups to be applied stretching exercises are gastrocinemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* 3 different functional stretching exercises will be applied;~* With the hands supported on the wall and with the help of the physiotherapist, the affected extremity is behind the knee in full extension m. gastrocnemius stretching exercise,~* With the hands supported on the wall and with the help of the physiotherapist, the knee is partially flexed, with the affected extremity behind. soleus stretching exercise,~* It is a stretching exercise that will be applied by asking the patient to squat without lifting his heels, with the patient's hands supported by the physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group / NDT program
Description: * Efforts to eliminate tone disorders,~* Sensory-perception-motor integrity development studies,~* Activities aimed at facilitating movements in daily life,~* Stretching and strengthening exercises due to muscle shortness and weakness,~* Studies to increase lower and upper extremity functionality,~* It will include the training of activities such as standing up, walking and balance.
Study: NCT05652738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive cooling application
Description: Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cooling using Blanket roll III
Description: standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics
Study: NCT05949567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urodynamic exam in sitting and lying position
Description: Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urodynamic exam in sitting and lying position
Description: Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)
Study: NCT05729503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: Cotton tip applicator pre-soaked with lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cotton tip applicator pre-soaked with saline
Study: NCT05162014

Intervention type: DRUG
Intervention: empagliflozin
Description: empagliflozin

Intervention type: DRUG
Intervention: Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
Description: Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
Study: NCT05953090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-0940
Description: A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
Study: NCT05129007

Intervention type: DEVICE
Intervention: Oura ring
Description: Photopletysmography based noninvasive device
Study: NCT05022589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.
Study: NCT05543408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXERCISE
Description: individualized, progressive, exercise program
Study: NCT05547620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUS Online Real
Description: Stimulation using NeuroFUS device while standing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUS Online Sham
Description: Stimulation using NeuroFUS device while standing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUS Offline
Description: Stimulation using NeuroFUS device prior to standing
Study: NCT06498414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampin standard arm
Description: 120 doses daily self-administered rifampin at 10mg/kg/day (max 600mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin double dose
Description: 60 doses daily self-administered rifampin at 20 mg/kg (max. 1200 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin and rifapentine
Description: 30 doses daily self-administered levofloxacin (15 mg/kg, max 750mg/day and rifapentine (10mg/kg, max: 600mg)
Study: NCT04874519

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
Study: NCT06536959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine
Description: For AML patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~For MDS patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 14 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~The venetoclax starting dose is 100 mg on the first day, ramping up to 200 mg on the second day and finally 400 mg once daily. The steady daily dose (after ramp-up phase) should be reduced to 100 mg (coadministered with moderate CYP3A inhibitors or P-gp inhibitors) and 70 mg (coadministered with strong CYP3A4 inhibitors).
Study: NCT06035263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME
Description: the prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education programme:
Description: instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group.
Study: NCT06148415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fetal Heartbeat Monitoring Group
Description: Fetal Heartbeat Monitoring Group
Study: NCT06447311

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid gel
Description: Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.
Study: NCT06080100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon
Description: inhalation of xenon in a sub-narcotic dosage

Intervention type: OTHER
Group type: OTHER
Intervention: premedication hydroxyzine 25 mg
Description: taking anxiolytic 30 minutes before surgery
Study: NCT04632160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD System II
Description: The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
Study: NCT06002841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous treatment with EVs
Description: intravenous treatment with extracellular vesicles

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: intravenous treatment with placebo solution
Description: intravenous treatment with placebo solution (without extracellular vesicles)
Study: NCT04839328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg Hemay005
Description: Hemay005 is a small molecule PDE4 inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos are the same as drugs, but contain no Hemay005.
Study: NCT05388734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alternative medicine education consultation
Description: The intervention will consist in a 1h30 individual consultation with a GP physician. Patients will be able to ask any questions they have regarding treatments for their breast cancer delivered outside of the hospital. Topics such as benefit-risk ratios, placebo effects and expectancies from CAM will be discussed with the patients. This consultation will promote a shared-decision model to help patients better discuss these matters with their healthcare providers.
Study: NCT05488106

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 1.6mg/d
Description: Riboflavin 1.6mg/d
Study: NCT05661864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Tiered Systems of Support for Teacher Training
Description: In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
Study: NCT06158126

Intervention type: DRUG
Intervention: Initiating injectable PrEP during pregnancy
Description: Group 2a will include pregnant women who initiate injectable PrEP (CAB-LA) at enrollment into the study.

Intervention type: DRUG
Intervention: Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis
Description: Group 2b will include women using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis.
Study: NCT05541822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABN401
Description: Tablets~Route of Administration: Oral
Study: NCT06233162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat-Test product
Description: Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat-Reference product
Description: Febuxostat 80 mg tablets Manufactured by: Patheon France, France
Study: NCT05931471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt Intervention
Description: Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
Study: NCT05469425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative home-based exercise training
Description: Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program.
Study: NCT05488106

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 5mg/d
Description: Riboflavin 5mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 20mg/d
Description: Riboflavin 20mg/d
Study: NCT06461286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYC-001
Description: Single Group Assignment
Study: NCT05563766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
Study: NCT06355063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX® nsPFA™ Cardiac Surgery System
Description: Adult patients presenting to the investigational center that are to undergo non-emergent concomitant cardiac surgical procedure(s), scheduled to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, ascending aortic aneurysms, or coronary artery bypass procedures with history of documented atrial fibrillation within one year prior to enrollment will be evaluated for eligibility and participation in the study.
Study: NCT04612244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FARAPULSE Pulsed Field Ablation System
Description: Ablation using the FARAPULSE Pulsed Field Ablation System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RadioFrequency and Cryoballoon Ablation
Description: Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
Study: NCT06383572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV
Study: NCT06549296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-04 CART Cell Injection
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study: NCT05477251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
Study: NCT05672095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo needle or core biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Given IV
Study: NCT06405841

Intervention type: OTHER
Intervention: Survey
Description: All patients will be asked to complete a survey at 1, 2, 4, 12 and 24 weeks from the trauma to assess their quality of life

Intervention type: OTHER
Intervention: Pain management
Description: All patients will be asked about their pain management at 1, 2, 4, 12 and 24 weeks from the trauma to assess if they are under medication and what kind of medication are they taking
Study: NCT05824871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine
Description: Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline
Description: Bedaquiline will be administered as a loading dose for 2 weeks (400 mg once daily) and a maintenance dose (200 mg three times per week, with at least 48 hours between doses) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for Sudapyridine.
Study: NCT05571384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity body-weight circuit
Description: Bodyweight and suspension training equipment (TRX® Fit System) with modified movements. Modified Squats: participants will be instructed to hold the handles of the band with arms extended, participants will then lean back in a standing position and perform a squat within a comfortable range of motion while weight is being distributed to the band. Modified Rows: participants will grab the bands with arms and legs extended. They will find a comfortable angle by which to perform a row (pulling the handles to the rib cage) with arms at a 45-degree angle. Modified Push-Ups: perform push-ups on their knees with a flat back and hands underneath their shoulders. They will be instructed to lower their chest towards the ground in a controlled manner and as far as comfort will allow them. Modified Crunches: participants will lay on their back with feet approximately 8-10 inches from their buttocks, and asked to lift their shoulders slightly off the ground.
Study: NCT06308562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuzzy Wale Compression Stockinet
Description: EdemaWear is a tubular, circular knit elastic stockinet fabricated with elastic, vertically oriented fuzzy wales, with the compression provided by the elastic, horizontal oriented Lycra® spandex yarns knitted in between. The stockinet is applied from the foot to the popliteal crease, over the affected area. EdemaWear can be applied in direct contact with the skin or over a wound care dressing. Sizing is based on leg circumference. EdemaWear is indicated for edema management of various etiologies (lymphedema, chronic venous insufficiency, congestive heart failure), and optimizing wound healing. The stockinette is often combined with other boxed compression sets. The manufacturer's stated dosage of EdemaWear is 8-12mmHg when used alone.
Study: NCT06527755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen Solution for Injection
Description: an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg.